Sonnet biotherapeutics regains compliance with nasdaq minimum bid price requirement

Princeton, nj / accesswire / october 4, 2022 / sonnet biotherapeutics holdings, inc. (nasdaq:sonn) (the "company" or "sonnet biotherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from the nasdaq stock market llc (nasdaq) on october 3, 2022 informing sonnet that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) (the "rule") for continued listing on the nasdaq capital market. in order to regain compliance with the rule, the company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.
SONN Ratings Summary
SONN Quant Ranking